Development and Evaluation of Multilayered Layered Matrix Tablets of Water Soluble Drug

Ravi Shekhar1*, P. Sharma2

1Department of Pharmacy, Dr. Bhimrao Ambedkar University, Agra, Uttar Pradesh, India
2Department of Pharmacology, S. N. Medical College, Agra, Uttar Pradesh, India

ABSTRACT
A new approach to zero-order drug delivery that includes geometric factors is described. Systems such as multilayered tablets and other geometrically altered devices have been created to perform this function. The multi-layered matrix system overcomes inherent disadvantages of non-linearity associated with diffusion controlled matrix devices by providing additional release surface with time to compensate for the decreasing release rate. These formulations designed to deliver the drug at predetermined rate, maintain therapeutically effective concentrations in systemic circulation for prolonged period of time. Recently, pharmaceutical research has focused on controlled drug delivery offer definite advantages over conventional release formulation of the same drug. Controlled delivery systems that can provide zero-order drug delivery have the potential for maximizing efficacy while minimizing dose frequency and toxicity. In the present study, guar gum was used as hydrophilic matrix carrier for designing oral controlled drug delivery systems of highly soluble drug lamivudine. Three layered matrix tablets of lamivudine prepared by wet granulation technique were subjected for various evaluating parameters and optimized.

Keywords: Multi layered tablet, lamivudine, controlled drug delivery system.

INTRODUCTION
Multi-layered matrix tablet is a drug delivery device, which comprises a matrix core containing the active solute and one, or more barriers (modulating layers) incorporated during the tableting process. The modulating layers delay the interaction of active solute with dissolution medium, by limiting the surface available for the solute release and at the same time controlling solvent penetration rate. In this device, the coat layers prevent the water penetration, through the protected core for some duration. This results in
reduced hydration rate and controlled area for solute release at the core. Thus burst effect can be smoothed and the release can be maintained at a relatively constant level during the barrier layers’ swelling and erosion process. After this phase, during the subsequent portion of the dissolution process, these swollen barriers are erosion dominated and the surface available for drug release slowly increases. In this way the decrease of delivery rate due to the increase of diffusion path-length (saturation effect) is counterbalanced by the simultaneous increase of the area available for drug release. By this way, combining a time-dependent control of the hydration rate of the device with the reduction of tablet surface exposed to the dissolution medium, it is feasible to achieve a linear release profile. It is also possible to obtain various dissolution patterns such as multi modal, pulsatile or delayed delivery, extended release (characterized by reasonably constant rate) for different drugs by varying the formulations of layers. In all the applications, the multi-layered system should swell gel and finally erode completely, leaving negligible residue in the gastrointestinal tract. The system is a unique drug delivery device, which overcomes the major disadvantage of non-linear release associated with most diffusion controlled matrix devices. This system also has the advantage of being compatible with conventional manufacturing methods.  

MATERIALS AND METHODS
Lamivudine was supplied by Aurobondo Pharma Ltd, Hyderabad, as a gift sample, guar gum, hydroxyl propyl methyl cellulose, starch, talc and magnesium stearate were obtained from Central Drug House (P) Ltd, New Delhi. All other ingredients used were of analytical grade and used as provided. Spectrophotometric studies carried out by using double beam UV spectrometer, Pharmaspec 1800, Shimadzu, Japan.

Preparation of multi layered tablet
Preparation of granules for middle layer
Lamivudine granules were prepared using 20% to 30% by weight of guar gum as a matrix former, by using the wet granulation method. HPMC was used as diluent, and guar gum was included in the formulation in various proportions. The compositions of guar gum matrix granules formulations used in the study containing 200 mg of lamivudine in each case are shown in Table 1. The powders were blended in poly bags and granulated with 10% w/v starch paste. The wet mass was screened through sieve no 16 and the granules were dried in air at room temperature for half an hour. The dried granules were shifted through sieve no 22 and the granules were lubricated with magnesium stearate (2% w/w) and followed by addition of (1% w/w) talc. Release-retardant layers were also prepared by wet granulation method using 10% w/v starch paste as binder. The composition of release retardant layer in each case is shown in Table 1.

1. The formulation of three layered matrix tablet were made using different combination of drug loaded matrix layer (M1-M3) and release retardant layers (T1- T3) and formulation codes are presented in Table 1.  

### Table 1: Composition (in mg) of Lamivudine Middle Matrix Layer Containing 20% (M1), 25% (M2) and 30% (M3) by Weight of Guar Gum and Composition (in mg) of Release Retardant Layer Containing 70% (T1), 75% (T2) and 80% (T3) by Weight of Guar Gum

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>M1</th>
<th>M2</th>
<th>M3</th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamivudine</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Guar gum</td>
<td>80</td>
<td>100</td>
<td>120</td>
<td>140</td>
<td>150</td>
<td>160</td>
</tr>
<tr>
<td>Starch paste (10% w/v)</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>HPMC</td>
<td>68</td>
<td>68</td>
<td>68</td>
<td>34</td>
<td>24</td>
<td>14</td>
</tr>
<tr>
<td>Talc</td>
<td>04</td>
<td>04</td>
<td>04</td>
<td>02</td>
<td>02</td>
<td>02</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>08</td>
<td>08</td>
<td>08</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Weight of Middle Layer Each</td>
<td>400</td>
<td>400</td>
<td>400</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Total Weight of layered tablet (mg)</td>
<td>800</td>
<td>800</td>
<td>800</td>
<td>800</td>
<td>800</td>
<td>800</td>
</tr>
</tbody>
</table>

Preparation of three layer matrix tablets

The three layered matrix tablets of lamivudine containing 200 mg of controlled release dose were prepared by wet granulation technique. The layered tablets containing 200 mg of each release retardant layer of guar gum granules on both sides of middle matrix layer thus resulted in tablet with a total weight of 800 mg. Initially, the volume of die was adjusted equivalent to total weight of three-layer matrix tablet (800 mg). Then preweighed amount of guar gum granules equivalent to bottom layer (200 mg) was taken and placed in the die cavity and slightly compressed for uniform spreading. The upper punch was lifted up, and 400 mg of drug granules were placed over the bottom layer of guar gum granules (200 mg) in the die cavity (Figure 1) and again slightly compressed. The remaining volume of die cavity was filled with preweighed amount of guar gum granules equivalent to top layer and finally compressed with maximum force of compression on a single station punching machine.

### Fig. 1: Approach of three layer matrix tablet

**Release retardant layer (200 mg)**

**Middle layer containing drug (400 mg)**

**Release retardant layer (200 mg)**

**Evaluation methods for layered matrix tablets**

Diameter and Thickness

Diameter and thickness was measured using instrument vernier calliper. Three tablets from each formulation were selected and diameter and the crown thickness were measured with a vernier calliper and an average of six determinations was established.

**Hardness**

Pfizer hardness tester was used to determine the hardness of three tablets from each formulation. The tablet was placed between two plungers containing a
compressible spring. The pressure required for the tablet to just crack was recorded directly on the gauge attached to the spring.

**Weight variation test**

Weight variation test was performed for twenty tablets from each batch using an electronic balance (K Roy, India) and average values were calculated. [8]

**Percentage drug content**

The tablet of each formulation (F1-F9) was weighed and powdered. Each tablet of lamivudine containing quantity equivalent to 200 mg was taken and transferred to a 100 ml volumetric flask and extracted with double distilled water and the percentage drug content was calculated from the calibration curve of lamivudine in double distilled water. An average of values was calculated mean ± S.D for three determinations.

**In-vitro drug release studies**

**Preparation of simulated gastric fluid (pH 1.2 Buffer)**

8.5 ml concentrated hydrochloric acid was dissolved in distilled water and diluted to 1000 ml to give 0.1 N hydrochloric acid. 0.85 ml concentrated hydrochloric acid was dissolved in distilled water and diluted to 1000 ml to give 0.01 N hydrochloric acid and pH 1.2 was adjusted with the help of dilute acid and base.

**Preparation of simulated intestinal fluid (pH 7.4 buffer)**

50 ml of 0.2M Potassium di-hydrogen phosphate was placed in a 200 ml volumetric flask, 49.1 ml of 0.2M Sodium hydroxide was added to it and the volume was made up to 200 ml with distilled water.

**Preparation of 0.2 M Potassium dihydrogen phosphate**

Dissolved 27.218 g of Potassium dihydrogen phosphate was dissolved in small amount of distilled water and the volume was made up with 1000 ml of distilled water.

**Preparation of 0.2 M Sodium hydroxide**

Dissolved 8.0 g of Sodium hydroxide in distilled water and volume was made up to 1000 ml with distilled water. [9]

**Drug excipients compatibility studies**

Fourier transform infrared (FTIR) spectra were also recorded to assess the chemical interaction or changes during formulation preparation. FTIR spectra of the pure drug, multi layered formulation of drug with different polymers were recorded in potassium bromide disc using a Shimadzu Model 8400 FTIR spectrometer.

**Images of layered matrix tablets**

The photographs of multi-layered tablets and its cross section were taken before and after swelling for three hours in distilled water by digital camera. [10]

**SEM studies of three layered matrix tablet**

The three-layered matrix tablet were cut into two halves by use of a sharp razor and coated with gold palladium under an argon atmosphere using a gold sputter module in a high vacuum evaporator. The gold palladium coated tablets were then observed with a scanning electron microscope.

**Stability studies**

Stability studies were carried out as per ICH Q1A stability testing guidelines for zone III. The formulated three-layered matrix tablets were subjected to storage condition of 40°C ± 2.0/ 75% RH ± 5 for 3 months. The sampling intervals were 0, 1, 2, and 3 months. The samples were evaluated for hardness and percentage drug content. [11]

**RESULTS AND DISCUSSION**

**Diameter and Thickness**

Three tablets from each formulation were selected and diameter and the crown thickness were measured with a vernier caliper and an average of six determinations was calculated and the mean values for diameter and thickness are tabulated in Table 2 and indicating appropriateness of the tooling used for compression.

**Hardness**

The hardness of tablets formulated (F1-F9) was evaluated using Pfizer hardness tester. The mean values of hardness of multi-layered tablets were in the range of 3.43-4.03 kg (Table 2). For the purpose of study, a tablet with hardness of more than 3 kg was selected as optimum value as it did not present handling problems. Thus all the formulations passed the above mentioned criteria.

**Weight Variation**

Twenty tablets from each batch were randomly selected and weighed and the average weight was calculated, not more than two of the individual weight deviated from the average weight by more than the 5% of average weight percentage as per IP limit (800 mg ± 40) and none deviated more than twice of that and the tablets passed the weight variation test and limits given in Indian pharmacopoeia. [9]

**Percentage Drug Content**

Lamivudine three-layer matrix tablets were tested for their percentage drug content. All the formulations of lamivudine tablets confirmed the drug content test as
the drug content was well within the range of contained $97.923 \pm 1.98 - 100.84 \pm 0.543$ (Table 2), indicating uniform mixing of guar gum, drug and other formulation excipients. [12]

These effects, possibly more effective in the initial phase of the dissolution process and less pronounced as swelling proceeds, lead to linearization of the release profile.

The drug release mechanism from the three-layered tablets involves the following sequence. In initial phase, barriers applied to the core are able to delay the interaction of the core with the dissolution medium by reducing the surface available for drug release and by limiting the solvent penetration rate. Thus, in this system the burst effect is controlled and the area available for drug release is maintained at relatively at constant level. The percentage in vitro drug release (Figure 2) of formulations (F1-F3) ranges from 99.145 ± 1.477 to 87.321 ± 2.329, similarly in case of formulation (F4-F6) the drug released up to 90.678 ± 2.530 to 84.86 ± 3.386 (Figure 3) and Figure 4 shows 83.591 ± 4.668 to 77.887 ± 2.165 for formulation (F7-F9). Thus on the basis of drug release, this is evident that on increasing the amount of guar gum in release retardant layers from 70% to 80% by weight on both sides of middle matrix layer the percentage cumulative release of all formulations decreased.

Drug excipients incompatibility studies

The Figure 5 clearly showed that there were no major changes in the DSC thermograms of pure drugs in presence of excipients, indicating absence of interactions between the drug and other excipients. [13]

**In-vitro drug release studies**

The three-layer matrix tablet that restricts the matrix area exposed to the dissolution medium may lead to a dual control in the system performance. This is possible for two reasons (a) matrix hydration rate and the consequent swelling are lowered and (b) the surface through which the drug can be delivered is reduced.

The drug release mechanism from the three-layered tablets involves the following sequence. In initial phase, barriers applied to the core are able to delay the interaction of the core with the dissolution medium by reducing the surface available for drug release and by limiting the solvent penetration rate. Thus, in this system the burst effect is controlled and the area available for drug release is maintained at relatively at constant level. The percentage in vitro drug release (Figure 2) of formulations (F1-F3) ranges from 99.145 ± 1.477 to 87.321 ± 2.329, similarly in case of formulation (F4-F6) the drug released up to 90.678 ± 2.530 to 84.86 ± 3.386 (Figure 3) and Figure 4 shows 83.591 ± 4.668 to 77.887 ± 2.165 for formulation (F7-F9). Thus on the basis of drug release, this is evident that on increasing the amount of guar gum in release retardant layers from 70% to 80% by weight on both sides of middle matrix layer the percentage cumulative release of all formulations decreased.

**Drug excipients incompatibility studies**

The Figure 5 clearly showed that there were no major changes in the DSC thermograms of pure drugs in presence of excipients, indicating absence of interactions between the drug and other excipients. [13]
Scanning electron microscopy (SEM) studies of three layer matrix tablet

SEM was carried out to study the formation of three-layer tablet matrix of lamivudine. The images clearly showed the three distinct layers (Figure 7 a-c) and were used to determine thickness of release retardant layers and the middle matrix layer.

Stability studies

Based on the results of the in-vitro drug release studies, three-layer gum matrix tablets of lamivudine are found to provide the required oral controlled drug delivery. Hence, stability studies were carried out by storing the selected formulation at 40°C/75% RH for 3 months (climatic zone III conditions for accelerated testing) to assess their long-term stability. At the end of the storage period, studies were conducted on lamivudine three-layer matrix tablets to assess their stability with respect to their physical appearance, hardness, drug content and release characteristics. The three-layer tablets after storing at 40°C/75% RH for 3 months showed (Table 3a and Table 3b), no significant change either in physical appearance, drug content or in dissolution pattern.

Table 3 (a): Stability Data of Selected Layered Tablet Formulation

<table>
<thead>
<tr>
<th>Time Interval (Month)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical Appearance</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Hardness (kg)</td>
<td>4.03 ± 0.098</td>
<td>3.91 ± 0.512</td>
<td>3.97 ± 0.215</td>
<td>4.01 ± 0.332</td>
</tr>
<tr>
<td>Percent Drug Content</td>
<td>97.923 ± 1.98</td>
<td>97.54 ± 2.22</td>
<td>98.82 ± 1.04</td>
<td>99.04 ± 0.82</td>
</tr>
</tbody>
</table>

Table 3 (b): Percent Cumulative Drug Release of Three Layer Matrix Tablet before and after Stability Studies of Selected Formulation F9

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time (Month)</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>8.786</td>
<td>9.521</td>
<td>8.592</td>
<td>8.810</td>
</tr>
<tr>
<td>1</td>
<td>12.782</td>
<td>12.652</td>
<td>12.752</td>
<td>12.712</td>
</tr>
<tr>
<td>4</td>
<td>17.409</td>
<td>18.051</td>
<td>18.520</td>
<td>18.259</td>
</tr>
<tr>
<td>8</td>
<td>32.697</td>
<td>32.991</td>
<td>33.012</td>
<td>32.698</td>
</tr>
<tr>
<td>10</td>
<td>39.521</td>
<td>40.052</td>
<td>40.567</td>
<td>40.025</td>
</tr>
<tr>
<td>12</td>
<td>47.757</td>
<td>48.251</td>
<td>48.658</td>
<td>47.582</td>
</tr>
<tr>
<td>16</td>
<td>57.986</td>
<td>58.101</td>
<td>58.326</td>
<td>58.321</td>
</tr>
<tr>
<td>20</td>
<td>77.887</td>
<td>78.919</td>
<td>78.215</td>
<td>78.214</td>
</tr>
</tbody>
</table>

It was possible to design a novel triple layered tablet dosage form based on multi-layered tablet technology and the desired surface area exposed per unit time. Successful formulation of various highly soluble drugs laminated with hydrophilic matrices was also possible and it was feasible to achieve a variety of drug release profiles, such as zero order, first order and multi-modal, by slightly varying the breakup of drug content between the layers and the polymer concentration and composition in core tablet. The system has the advantages of relatively low cost and potentially feasible to large-scale production using layered tablet process.

REFERENCES

8. Indian Pharmacopoeia, Controller of publication New Delhi, 1996a, Volume 2, 736.
9. Indian Pharmacopoeia, Controller of publication New Delhi, 1996b, Volume 2, A-144-145